Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms

Polish Journal of Pharmacology

Volumn 55, Issue 2, 2003, Pages 133-154

  Pietraszek, Małgorzata ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Glutamate; NMDA receptors; Phencyclidine; Schizophrenia

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; 3 (2 CARBOXY 2 PHENYLETHENYL) 4,6 DICHLORO 1H INDOLE 2 CARBOXYLIC ACID; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 5,7 DICHLORO 1,2,3,4 TETRAHYDRO 4 (3 PHENYLUREIDO) 2 QUINOLINECARBOXYLIC ACID; AMPA RECEPTOR; AMPHETAMINE; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DIZOCILPINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; HALOPERIDOL; IFENPRODIL; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; KETAMINE; L 689 560; MDL 105 519; MMK 801; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SEROTONIN AGONIST; UNINDEXED DRUG;

AUTOPSY; DRUG ACTIVITY; DRUG INHIBITION; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; IN VIVO STUDY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PSYCHOSIS; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; GLUTAMIC ACID; HUMANS; NEURONS; RECEPTORS, DOPAMINE; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0038446751     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (213)

1. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., Breier A.: Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Amer. J. Psychiat., 1999, 156, 1646-1649.
2. Aghajanian G.K., Marek G.J.: Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Rev., 2000, 31, 302-312.
3. Akbarian S., Smith M.A., Jones E.G.: Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. Brain Res., 1995, 699, 279-304.
4. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E., Jones E.G.: Selective alternation in gene expression for NMDA receptor subunit in prefrontal cortex of schizophrenics. J. Neurosci., 1996, 16, 19-30.
5. Al-Amin H.A., Weinberger D.R., Lipska B.K.: Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus. Behav. Pharmacol., 2000, 11, 269-278.
6. Allen R.M., Young S.J.: Phencyclidine-induced psychosis. Amer. J. Psychiat., 1978, 135, 1081-1084.
7. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X., Cappiello A., Krystal J.H.: Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiat., 2000, 57, 270-276.
8. Aparicio-Legarza M.I., Davis B., Hutson P.H., Reynolds G.P.: Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci. Lett., 1998, 241, 143-146.
9. Arnt J., Skarsfeldt T.: Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology, 1998, 18, 63-101.
10. Aultman J.M., Moghaddam B.: Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology, 2001, 153, 353-364.
11. Bakshi V.P., Geyer M.A.: Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antypsychotic olanzapine. Psychopharmacology, 1995, 122, 198-201.
12. Bakshi V.P., Swerdlow N.R., Geyer M.A.: Clozapine antagonizes phencyclidine-induced deficits in sensori-motor gating of the startle response. J. Pharmacol. Exp. Ther., 1994, 271, 787-794.
13. Balla A., Koneru R., Smiley J., Sershen H., Javitt D.C.: Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology, 2001, 25, 157-164.
14. Banerjee S.P., Zuck L.G., Yablonsky-Alter E., Lidsky T.I.: Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. NeuroReport, 1995, 6, 2500-2504.
15. Benes F.M., Todtenkopf M.S., Kostoulakos P.: Glu-R5,6,7 subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives. Hippocampus, 2001, 11, 482-491.
16. Breese C.R., Freedman R., Leonard S.: Glutamate receptors subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res., 1995, 674, 82-90.
17. Breier A., Su T.-P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Picar A.: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron tomography method. Proc. Nat. Acad. Sci. USA, 1997, 94, 2569-2574.
18. Bubser M., Tzschentke T., Hauber W.: Behavioural and neurochemical interaction of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats. J. Neural Transm. Gen. Sect., 1995, 101, 115-126.
19. Buller A.L., Larson H.C., Schneider B.E., Beaton J.A., Morrisett R.A., Monaghan D.T.: The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J. Neurosci., 1994, 14, 5471-5484.
20. Carlsson M., Carlsson A.: The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm., 1989, 75, 221-226.
21. Carlsson M., Carlsson A.: Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci., 1990, 13, 272-276.
22. Carlsson M., Svensson A.: Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol. Biochem. Behav., 1990, 36, 45-50.
23. Carlsson A., Waters N., Waters S., Carlsson M.L.: Network interactions in schizophrenia - therapeutic implication. Brain Res. Rev., 2000, 31, 342-349.
24. Cartmell J., Monn J.A., Schoepp D.D.: The metabotropic glutamate receptor agonists LY354740 and LY379368 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther., 1999, 291, 161-170.
25. Chen A.C., McDonald B., Moss S.J., Gurling H.M.D.: Gene expression studies of mRNA encoding the NMDA receptor subunits NMDAR1, NMDA2A, NMDA2B, NMDA2C, and NMDA2D following long-term treatment with cis- and trans-flupentixol as a model for understanding the mode of action of schizophrenia drug treatment. Mol. Brain Res., 1998, 54, 92-100.
26. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W.: Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology, 1995, 120, 67-74.
27. Corre S., Harper C.G., Lopez P., Ward P., Catts S.: Increased levels of expression of an NMDAR1 splice variant in the superior temporal gyrus in schizophrenia. NeuroReport, 2000, 11, 983-986.
28. Corso T.D., Sesma M.A., Tenkova T.I., Der T.C., Wozniak D.F., Farber N.B., Olney J.W.: Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res., 1997, 752, 1-14.
29. 3H]ifenprodil binding in rat brain membranes. J. Pharmacol. Exp. Ther., 1997, 280, 584-592.
30. Coyle J.T.: The nagging question of the function of N-acetylaspartylglutamate. Neurobiol. Dis., 1997, 4, 231-238.
31. Crook J.M., Akil M., Law B.C.W., Hyde T.M., Kleinman J.E.: Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol. Psychiat., 2002, 7, 157-164.
32. Cull-Candy S., Brickley S., Farrant M.: NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol., 2001, 11, 327-335.
33. Das S., Saski Y.F., Rothe T., Premkumars L.S., Takasu M., Crandall J.E., Dikkes P., Conner D.A., Rayudu P.V., Cheung W., Chen H.S.V., Lipton S.A., Nakanishi N.: Increased NMDA current and spine density in mice lacking NMDA receptor subunit NR3A. Nature, 1998, 393, 377-381.
34. Deakin J.F.W., Slater P., Simpson M.D.C., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G. P., Cross A. J.: Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem., 1989, 52, 1781-1786.
35. Dracheva S., Marras S.A.E., Elhakem S.L., Kramer F.R., Davis K.L., Haroutunian V.: N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Amer. J. Psychiat., 2001, 158, 1400-1410.
36. Drapalski A.L., Rosse R.B., Peebles R.R., Schwartz B.L., Marvel C.L., Deutsch S.I.: Topiramate improves deficit symptoms in patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin. Neuropharmacol., 2001, 24, 290-294.
37. Dursun S.M., Deakin J.F.W.: Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J. Psychopharmacol., 2001, 15, 297-301.
38. Eastwood S.L., Kerwin R.W., Harrison P.J.: Immunoautoradiographic evidence for loss of α-[3H]amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol. Psychiat., 1997, 41, 636-643.
39. Eastwood S.L., McDonald B., Burnet P.W.J., Beckwith J.P., Kerwin R.W., Harrison P.J.: Decreased expression of mRNA encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res., 1995, 29, 211-223.
40. Ellenbroek B.A, Colls A.R.: The neurodevelopment hypothesis of schizophrenia: Clinical evidence and animal models. Neurosci. Res. Commun., 1998, 22, 127-136.
41. Ellison G.: Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res. Rev., 1994, 19, 223-239.
42. Ellison G.: The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of dementias. Brain Res. Rev., 1995, 20, 250-267.
43. Erhardt S., Blennow K., Nordin C., Skogh E., Lindstrom L.H., Engberg G.: Kynurenic acid levels are elevated in cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett., 2001, 313, 96-98.
44. Evins A.E., Amico E., Posever T.A., Toker R., Goff D.C.: D-Cycloserine added to risperidone in patient with primary negative symptoms of schizophrenia. Schizophr. Res., 2002, 56, 19-23.
45. Evins A.E., Fitzgerald S.M., Wine L., Rosselli R., Goff D.C.: Placebo-controlled trial of glycine added to clozapine in schizophrenia. Amer. J. Psychiat., 2000, 157, 826-828.
46. Farber N.B., Foster J., Duhan N.L., Olney J.W.: Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res., 1996, 21, 33-37.
47. Farber N.B., Kim S.H., Dikranian K., Jiang X.P., Heinkel C.: Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol. Psychiat., 2002, 7, 32-43.
48. Farber N.B., Price M.T., Labruyere J., Nemnich J., St Peter H., Wozniak D.F., Olney J.W.: Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol. Psychiat., 1993, 34, 119-121.
49. Feifel D., Priebe K.: The effects of chronic haloperidol on intact and dizocilpine-induced sensorimotor gating. Psychopharmacology, 1999, 146, 175-179.
50. Fitzgerald L.W., Deutch A.Y., Gasic G., Heinemann S.F., Nestler E.: Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci., 1995, 15, 2453-2461.
51. Fletcher E.J., MacDonald J.F.: Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur. J. Pharmacol., 1993, 235, 291-295.
52. Fonnum F.: Neurochemical studies on glutamate-mediated neurotransmission. In: Excitatory Amino Acids. Eds. Meldrum B.S., Moroni F., Simon R.P., Woods J.H., Raven Press Ltd., NY, 1991, 15-25.
53. Freed W., Dillon-Carter O., Kleinman J.: Properties of [3H]AMPA binding in postmortem human brain from psychotic subjects and controls: increases in caudate nucleus associated with suicide. Exp. Neurol., 1993, 121, 48-56.
54. Freeman A.S., Bunney B.: The effect of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur. J. Pharmacol., 1984, 104, 287-293.
55. Gandolfi O., Dall'Olio R.: Modulatory role of dopamine on excitatory amino acid receptors. Prog. Neuro-Psych. Biol. Psych., 1996, 20, 659-671.
56. Gao X., Saki K., Roberts R.C., Conley R.R., Tamminga C.A.: Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Amer. J. Psychiat., 2000, 157, 1141-1149.
57. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R.: Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: decade in review. Psychopharmacology, 2001, 156, 117-154.
58. Geyer M.A., Swerdlow N.R., Mansbach R.S., Braff D.L.: Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain. Res. Bull., 1990, 25, 485-498.
59. 3H]MK-801 binding sites in the rat brain: a side-preference action in cortical areas. Brain Res., 1997, 762, 216-218.
60. Goff D.C., Tsai G., Levitt J., Manoach D., Schoenfeld D.A., Hayden D.L., McCarley R., Coyle J.T.: A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiat., 1999, 56, 21-27.
61. Goff D.C., Tsai G., Manoach D.S., Coyle J.T.: Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia, Amer. J. Psychiat., 1995, 152, 1213-1215.
62. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T.: D-cycloserine added to clozapine for patients with schizophrenia. Amer. J. Psychiat., 1996, 153, 1628-1630.
63. Goldman-Rakic P.S., Muly E.C., Williams G.V.: D1 receptors in prefrontal cells and circuits. Brain Res. Rev., 2000, 31, 295-301.
64. Grimwood S., Slater P., Deakin J.F. W., Hutson P.H.: NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. NeuroReport, 1999, 10, 461-465.
65. Grunze H., Greene R. W., Moller H.-J., Meyer T., Walden J.: Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current. Brain Res., 1998, 791, 330-334.
66. Grunze H.C.R., Rainnie D.G., Hasselmo M.E., Barkai E., Hearn E.F., McCarley R.W., Greene R.: NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci., 1996, 16, 2034-2043.
67. Harrison P.J., McLaughlin D., Kerwin W.: Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet, 1991, 337, 450-542.
68. Healy D.J., Haroutunian V., Powchik P., Davidson M., Davis K.L., Watson S.J., Meador-Woodruff J.H.: AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology, 1998, 19, 278-286.
69. Heresco-Levy U., Javitt D.C., Ermilov M., Silipo G., Lichtenstein M.: Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiat., 1999, 56, 29-36.
70. Hoffman D.C.: Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm.-Gen. Sect., 1992, 89, 1-10.
71. Hoffman D.C., Donovan H., Cassella J.V.: The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology, 1993, 111, 339-344.
72. Humphries C., Mortimer A., Hirsch S., de Belleroche J.: NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. NeuroReport, 1996, 7, 2051-2055.
73. Ibrahim H.M., Hogg A.J., Healy D.J., Haroutunian V., Davis K.L., Meador-Woodruff J.H.: Ionotropic glutamate receptors binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Amer. J. Psychiat., 2000, 157, 1811-1823.
74. Ikonomidou C., Bittigau P., Koch C., Genz K., Hoerster F., Felderhoff-Mueser U., Tenkova T., Dikranian K., Olney J.W.: Neurotransmitters and apoptosis in the developing brain. Biochem. Pharmacol., 2001, 62, 401-405.
75. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Stefovska V., Turski L., Olney J.V.: Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science, 1999, 283, 70-74.
76. Ilyin V.I., Whittemore E.R., Guastella J., Weber E., Woodward R.M.: Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol. Pharmacol., 1996, 50, 1541-1550.
77. Ishimaru M., Kurumaji A., Toru M.: NMDA-associated glycine binding site increases in schizophrenic brains. Biol. Psychiat., 1992, 32, 379-381.
78. Ishimaru M.J., Toru M.: The glutamate hypothesis of schizophrenia. CNS Drugs, 1997, 7, 47-67.
79. Jackson D.M., Johansson C., Lindgren L.-M., Bengtsson A.: Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol. Biochem. Behav., 1994, 48, 465-471.
80. Javitt D.C., Balla A., Sershen H., Lajtha A.: Reversal of phencyclidine-induced effect by glycine and glycine transport inhibitors. Biol. Psychiat., 1999, 45, 668-679.
81. Jentsch J.D., Dazzi L., Chatwal J.P., Verrico C.D., Roth R.H.: Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci. Lett., 1998, 258, 175-178.
82. Jentsch J.D., Roth R.H.: The neuropsychopharmacology of phencyclidine: from NMDA receptor hypo-function to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 1999, 20, 201-225.
83. Jentsch D.J. Taylor J., Roth R.H.: Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology, 1998, 19, 105-113.
84. Jentsch J.D., Tran A., Le D., Youngren K.D., Roth R.H.: Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology, 1997, 17, 92-99.
85. Johansson C., Jackson D.M., Svensson L.: The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology, 1994, 116, 437-442.
86. Johnson K.M., Phillips M., Wang C., Kevetter G.A.: Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex. J. Neurosci. Res., 1998, 52, 709-722.
87. Kahn R.S., Davis K.L.: New developments in dopamine and schizophrenia. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom F.E., Kupfer D.J., Raven Press, Ltd., New York, 1995, 1193-1201.
88. Kane J.M.: Pharmacologic treatment of schizophrenia. Biol. Psychiat., 1999, 46, 1396-1408.
89. Keith V.A., Mansbach R.S., Geyer M.A.: Failure of haloperidol to block the effect of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol. Psychiat., 1991, 30, 557-566.
90. Kendrick S.J., Lynch D.R., Pritchett D.B.: Characterization of glutamate binding sites in receptors assembled from transfected NMDA receptor subunits. J. Neurochem., 1996, 67, 608-616.
91. Kerwin R., Patel S., Meldrum B.: Quantitive autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience, 1990, 39, 25-32.
92. Keverne E.B.: GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Brain Res. Bull., 1999, 48, 467-473.
93. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmüller B.: Low cerebral fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett., 1980, 20, 379-382.
94. Kim S.H., Price M.T., Olney J.W., Farber N.B.: Excessive cerebrocortical release of acetylocholine induced by NMDA antagonists is reduced by GABA-ergic and alpha2-adrenergic agonists. Mol. Psychiat., 1999, 4, 344-352.
95. Knable M.B., Weinberger D.R.: Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol., 1997, 11, 123-131.
96. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J. Neural Transm., 1989, 77, 231-236.
97. Korpi E.R., Kleiman J.E., Goodman S.I., Wyatt R.J.: Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiat. Res., 1987, 22, 291-301.
98. Krystal J.H., Belger A., D'Souza D.C., Anand A., Charley D.C., Aghajanian G.K., Moghaddam B.: Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology, 1999, 21, 143-157.
99. Kurumaji A., Ishimaru M., Toru M.: α-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to human cerebral cortical membranes: minimal changes in postmortem brains of chronic schizophrenics. J. Neurochem., 1992, 59, 829-837.
100. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado, C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B.: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Nat. Acad. Sci. USA, 1996, 93, 9235-9240.
101. Laurie D.J., Seeburg P.H.: Ligand affinities at recombinant N-methyl-D-asparate receptors depend on subunit composition. Eur. J. Pharmacol.-Molec. Pharm., 1994, 268, 335-345.
102. Leveque J.C., Macias W., Rajadhyaksha A., Carlson R.R., Barczak A., Kang S., Li X.M., Coyle J.T., Huganir R.L., Heckers S., Konradi C.: Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci., 2000, 20, 4011-4020.
103. Levis D.A.: GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res. Rev., 2000, 31, 270-276.
104. Lidsky T.I., Yablonsky-Alter E., Zuck L.G., Banerjee S.P.: Antipsychotic drug effects on glutamatergic activity. Brain Res., 1997, 764, 46-52.
105. Lipska B.K., Aultman J.M., Verma A., Weinberger D.R., Moghaddam B.: Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology, 2002, 27, 47-54.
106. Lipska B.K., Jaskiw G.E., Weinberger D.R.: Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology, 1993, 9, 67-75.
107. Lipska B.K., Swerdlow N.R., Geyer M.A., Jaskiw G.E., Braff D.L., Weinberger D.R.: Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology, 1995, 122, 35-43.
108. Lipska B.K., Weinberger D.R.: Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology, 1994, 10, 199-205.
109. Lipska B.K., Weinberger D.R.: To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology, 2000, 23, 223-239.
110. Liu J., Moghaddam B.: Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J. Pharmacol. Exp. Ther., 1995, 274, 1209-1215.
111. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R.: Stu5dy of a new schizophrenomimetic drug - sernyl. Arch. Neurol. Psychiat., 1959, 81, 363-369.
112. Lynch D.R., Gallagher M.J.: Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors. J. Pharmacol. Exp. Ther., 1996, 279, 154-161.
113. Maj J., Rogóz Z., Skuza G.: Locomotor hyperactivity induced by MK-801 in rats. Pol. J. Pharmacol., 1991, 43, 449-458.
114. Malhotra A.K., Adler C.M, Kennison S.D., Elman I, Pickar D., Breier A.: Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiat., 1997, 42, 664-668.
115. Malhotra A.K., Pinalis D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A.: Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology, 1997, 17, 141-150.
116. Mansbach R.S., Geyer M.A., Braff D.L.: Dopaminergic stimulation disrupts sensorimotor gating. Psychopharmacology, 1988, 94, 507-514.
117. Marchese G., Casu M.A., Bartholini F., Ruiu S., Saba P., Gessa G.L., Pani L.: Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur. J. Neurosci., 2002, 15, 1187-1196.
118. 1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur. J. Pharmacol., 1999, 367, 197-206.
119. 2A and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther., 2000, 292, 76-87.
120. Martin P., Carlsson M.L., Hjorth S.: Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rat. NeuroReport, 1998, 9, 2985-2988.
121. Martinez Z.A., Oostwegel J., Geyer M., Ellison G.D., Swerdlow N.R.: "Early" and "late" effects of sustained haloperidol on apomorphine- and phencyclidine-induced sensorimotor gating deficits. Neuropsychopharmacology, 2000, 23, 517-527.
122. Mathe J.M., Nomikos G.G., Schilstrom B., Svensson T.H.: Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801)-induced hyperlocomotion and dopamine release in the nucleus accumbens. J. Neurosci. Res., 1998, 51, 583-592.
123. Matsuda K., Kamiya Y., Matsuda S., Yuzaki M.: Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability. Mol. Brain Res., 2002, 100, 43-52.
124. 2A receptors. Eur. J. Pharmacol., 1995, 280, R9-R11.
125. Maurice T., Vignon J., Kamenka J., Chicheportiche R.: Differential interaction of phencyclidine-like drugs with the dopamine uptake complex in vivo. J. Neurochem., 1991, 56, 553-559.
126. McCoy L., Cox C., Richfield E.K.: Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression. Synapse, 1998, 28, 195-207.
127. Meador-Woodruff J.H., Hogg A.J., Smith R.E.: Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res. Bull., 2001, 55, 631-640.
128. Meltzer H.Y.: The role of serotonin in antipsychotic drug action. Neuropsychopharmacology, 1999, 21, 106S-115S.
129. Meltzer H.Y., McGurk S.R.: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull., 1999, 25, 233-255.
130. Meshul C., Bunker G., Mason J., Allen C., Janowski A.: Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J. Neurochem., 1996, 67, 1965-1973.
131. Moghaddam B., Adams B.: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science, 1998, 281, 1349-1352.
132. Moghaddam B., Adams B., Verma A., Daly D.: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci., 1997, 17, 2921-2927.
133. Murase S., Mathe J.M., Grenhoff J., Svensson T.H.: Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J. Neural Transm.-Gen. Sect., 1993, 91, 13-25.
134. Narayanan S., Willins D., Dalia A., Wallace L., Uretsky N.J.: Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into ventral tegmental area and the nucleus accumbens. Pharmacol. Biochem. Behav., 1996, 54, 565-573.
135. Nishikawa T., Takashima M., Toru M.: Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci. Lett., 1983, 40, 245-250.
136. Noga J.T., Hyde T.M., Herman M.M., Spurney C.F., Bigelow L.B., Weinberger D.R., Kleiman J.E.: Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brain. Synapse, 1997, 27, 168-176.
137. Noga J.T., Wang H.: Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse, 2002, 45, 250-258.
138. Nudmamud S., Reynolds G.P.: Increased density of glutamate/N-methyl-D-aspartate receptors in superior temporal cortex in schizophrenia. Neurosci. Lett., 2001, 304, 9-12.
139. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C.: Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia Mol. Brain. Res., 1998, 56, 207-217.
140. Olney J.W., Farber N.B.: NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology, 1995, 13, 335-345.
141. Olney J.W., Newcomer J.W., Farber N.B.: NMDA receptor hypofunction model of schizophrenia. J. Psychiat. Res., 1999, 33, 523-533.
142. Olpe H.R., Koella W.P., Wolf P., Haas H.L.: The action of baclofen on neurons of the substantia nigra and of the ventral tegmental area. Brain Res., 1977, 134, 577-580.
143. Onn S.-P., West A.R., Grace A.A.: Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci., 2000, 23, 48-56.
144. Ossowska K.: The role of amino acids in experimental model of Parkinson's disease. J. Neural Transm.-Parkinsons. 1994, 8, 39-71.
145. Ossowska K., Pietraszek M., Wardas J.: Further evidence for the subsensitivity of striatal AMPA receptors, induced by chronic haloperidol administration: an autoradiographic study. Naunyn-Schmied. Arch. Pharmacol., 1996, 353, 384-388.
146. Ossowska K., Pietraszek M., Wardas J., Dziedzicka-Wasylewska M., Nowicka D., Wolfarth S.: Chronic treatments with haloperidol and clozapine alter the level of NMDA-R1 mRNA in the rat brain: an in situ hybridization study. Pol. J. Pharmacol., 2002, 54, 1-9.
147. Ossowska K., Pietraszek M., Wardas J., Nowak G., Wolfarth S.: Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn-Schmied. Arch. Pharmacol., 1999, 359, 280-287.
148. Ouagazzal A., Nieoullon A., Amalric M.: Locomotor activation induced by MK-801 in the rat: postsynaptic interaction with dopamine receptors in the ventral striatum. Eur. J. Pharmacol., 1994, 251, 229-236.
149. Parsons C.G., Danysz W., Quack G.: Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect., 1999, 11, 523-569.
150. Perry T.L.: Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett., 1982, 28, 81-85.
151. Pietraszek M., Gołembiowska K., Bijak M., Ossowska K., Wolfarth S.: Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies. Naunyn-Schmied. Arch. Pharmacol., 2002, 366, 417-424.
152. Pietraszek M., Ossowska K.: Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats. Naunyn-Schmied. Arch. Pharmacol., 1998, 357, 466-471.
153. Porter R.H.P., Eastwood S.L., Harrison P.J.: Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res., 1997, 751, 217-231.
154. Qin Z.-H., Zhang S.-P., Weiss B.: Dopaminergic and glutamatergic blocking drugs differentially regulate glutamic acid decarboxylase mRNA in mouse brain. Mol. Brain Res., 1994, 21, 293-302.
155. Richardson-Burns S.M., Haroutunian V., Davis K.L., Watson S.J., Meador-Woodruff J.H.: Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol. Psychiat., 1999, 47, 22-28.
156. Rigdon G.C., Viik K.: Prepulse inhibition as a screening test for potential antipsychotics. Drug Dev. Res., 1991, 23, 91-99.
157. Riva M.A., Tascedda F., Lovati E., Racagni G.: Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Mol. Brain. Res., 1997, 50, 136-142.
158. Roth B.L., Meltzer H.Y.: The role of serotonin in schizophrenia. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom F.E., Kupfer D.J., Raven Press, Ltd., New York, 1995, 1215-1227.
159. Sams-Dodd F.: Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol., 1996, 7, 3-23.
160. Sams-Dodd F.: Effects of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav. Pharmacol., 1997, 8, 196-215.
161. Sams-Dodd F.: Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology, 1998, 19, 18-25.
162. Schiffer W.K., Gerasimov M., Hofmann L., Marsteller D., Ashby C.R., Brodie J.D., Alexoff D., Dewey S.L.: Gamma-vinyl-GABA differentially modulates NMDA antagonist-induced increases in mesocortical versus mesolimbic DA transmission. Neuropsychopharmacology,
163. Schoepp D.D., Jane D.E., Monn J.A.: Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology, 1999, 38, 1431-1476.
164. Schroeder H., Grecksch G., Becker A., Bogerts B., Hoellt V.: Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion. Psychopharmacology, 1999, 145, 61-66.
165. Schwarcz R., Rassoulpour A., Wu H., Medoff D., Tamminga C.A., Roberts R.C.: Increased cortical kynurenate content in schizophrenia. Biol. Psychiat., 2001, 50, 521-530.
166. See R.E., Chapman M.A.: Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur. J. Pharmacol., 1994, 263, 269-276.
167. See R.E., Lynch A.M.: Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats. Eur. J. Pharmacol., 1996, 308, 279-282.
168. Seeman P.: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1987, 1, 133-152.
169. Seeman P.: Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology, 1992, 7, 261-284.
170. Shank R.P., Gardocki J.F., Streeter A.J., Maryanoff B.E.: An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia, 2000, 41, 3-9.
171. Sharp F.R, Tomitaka M., Bernaudin M., Tomitaka S.: Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia. Trends Neurosci., 2001, 24, 330-334.
172. Sherman A.D., Hegwood T.S., Baruah S., Waziri R.: Deficient NMDA-mediated glutamate release from synaptosomes od schizophrenics. Biol. Psychiat., 1991, 30, 1191-1198.
173. Shoham S., Javitt D.C., Heresco-Levy U.: Chronic high-dose glycin nutrition: effects on rat brain cell morphology. Biol. Psychiat., 2001, 49, 876-885.
174. Simpson M.D.C., Slater P., Deakin J.F.W., Royston M.C., Skan W.J.: Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci. Lett., 1989, 107, 211-215.
175. Simpson M.D.C., Slater P., Royston M.C., Deakin J.F.W.: Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effect of disease process and neuroleptic medication. Schizophr. Res., 1992, 6, 41-48.
176. Sitges M., Nekrassov V., Guarneros A.: Simultaneous action of MK-801 (dizocilpine) on dopamine, glutamate, aspartate and GABA release from striatum isolated nerve endings. Brain Res., 2000, 854, 48-56.
177. Snyder S.H., Ferris C.D.: Novel neurotransmitters and their neuropsychiatric relevance. Amer. J. Psychiat., 2000, 157, 1738-1751.
178. Sokolov B.P.: Expression of NMDAR1, GluR1, GluR7. and KA1 glutamate receptor mRNA is decreased in frontal cortex of "neuroleptic-free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J. Neurochem., 1998, 71, 2454-2464.
179. Spurney C.F., Baca S.M., Murray A.M., Jaskiw G.E., Kleinman J.E., Hyde T.M.: Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse, 1999, 34, 266-276.
180. Stefani A., Spadoni F., Siniscalchi A., Bernardi G.: Lamotrigine inhibits Ca2+ currents in cortical neurones: functional implications. Eur. J. Pharmacol., 1996, 307, 113-116.
181. Stone T.W.: Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev., 1993, 45, 309-379.
182. Sturgeon R.D., Fessler R.G., Meltzer H.Y.: Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavioral and ataxia in rats. Eur. J. Pharmacol., 1979, 59, 169-179.
183. Svensson T.H.: Dysfunctional brain dopamine system induced by psychomimetic NMDA-receptor antagonists and the effect of antipsychotic drugs. Brain Res. Rev., 2000, 31, 320-329.
184. Swanson C.J., Schoepp D.D.: The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-amino-bicyclo [3.1.0]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats. J. Pharmacol. Exp. Ther., 2002, 303, 919-927.
185. Swartz K.J., During M.J., Freese A., Beal M.F.: Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J. Neurosci., 1990, 10, 2965-2793.
186. Swerdlow N.R., Bakshi V., Geyer M.A.: Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther., 1996, 279, 1290-1299.
187. Swerdlow N.R., Braff D.L., Geyer M.A.: Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav. Pharmacol., 2000, 11, 185-204.
188. Swerdlow N.R., Keith V.A., Braff D.L., Geyer M.A.: Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J. Pharmacol. Exop. Ther., 1991, 256, 530-536.
189. Tarazi F.I., Florijn W.I., Creese I.: Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology, 1996, 128, 371-379.
190. Tascedda F., Blom J.M.C., Brunello N., Zolin K., Gennarelli M., Colzi A., Bravi D., Carra S., Racagni G., Riva M.A.: Modulation of glutamate receptors in response to the novel antipsychotic olnazapine in rats. Biol. Psychiat., 2001, 50, 117-122.
191. Tascedda F., Lovati E., Blom J.M.C., Muzzioli P., Brunello N., Racagni G,. Riva M.A.: Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic Seroquel (Quetiapine Fumarate). Neuropsychopharmacology, 1999, 21, 211-217.
192. Tiedtke P.I., Bischoff C., Schmidt W.J.: MK-801-induced streotypy and its antagonism by neuroleptic drugs. J. Neural Transm.-Gen. Sect., 1990, 81, 173-182.
193. Tiihonen J., Hallikainen T., Ryynanen O.-P., Repo-Tiihonen E., Kotilainen I., Eronen M., Toivonen P., Wahlbeck K., Putkonen A.: Lamotrigine in clozapine-resistant schizophrenia: a randomized placebo-controlled cross-over trial. Eur. Neuropsychopharmacology, 2002, 13, 263.
194. Toru M., Kurumaji A., Kumashiro S., Suga I., Tamashima M., Nishikawa T.: Excitatory amino acidergic neurons in chronic brain. Mol. Neuropharmacol., 1992, 2, 241-243.
195. Toru M., Watanabe S., Shibuya H., Nishikawa T., Noda K., Mitsushio H., Ishikawa H., Kurumaji A., Takashima M., Mataga N., Ogawa A.: Neurotransmitters, receptors and neuropeptides in postmortem brains of chronic schizophrenic patients. Acta Psychiatr. Scand., 1988, 78, 121-137.
196. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., Coyle J.T.: Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiat., 1995, 52, 829-836.
197. Tsai G., van Kammen D.P., Chen S., Kelley M.E., Grier A., Coyle J.T.: Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol. Psychiat., 1998, 44, 667-674.
198. Tsai G., Yang P., Chung L.C., Lange N.A., Coyle J.T.: D-serine added to antipsychotic for the treatment of schizophrenia. Biol. Psychiat., 1998, 44, 1081-1089.
199. Tsai G.E., Yang P., Chung L.-C., Tsai I.-C., Tsai C.-W., Coyle J.T.: D-serine added to clozapine for treatment of schizophrenia. Amer. J. Psychiat., 1999, 156, 1822-1825.
200. Ułas J., Nguyen L., Cotman C.W.: Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. NeuroReport, 1993, 4, 1049-1051.
201. 2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology, 1999, 20, 311-321.
202. Verma A., Moghaddam B.: NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci., 1996, 16, 373-379.
203. Waldmeier P.C., Martin P., Stocklin K., Porter C., Schmutz M.: Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn-Schmied. Arch. Pharmacol., 1996, 354, 164-472.
204. Wang C., Mcinnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wilney J.L., Johnson K.M.: Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implication for schizophrenia. Neuroscience, 2001, 107, 535-550.
205. Waziri R., Baruah S.: A hyperglycinergic rat model for the pathogenesis of schizophrenia: preliminary findings. Schizophr. Res., 1999, 37, 205-215.
206. Wedzony K., Gołembiowska K., Zazula M.: Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn-Schmied. Arch. Pharmacol., 1994, 350, 555-562.
207. Weinberger D.R.: Cell biology of the hippocampal formation in schizophrenia. Biol. Psychiat., 1999, 45, 395-402.
208. Willins D.L., Narayanan S., Wallace L.J., Uretsky N.J.: Role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK-801. Pharmacol. Biochem. Behav., 1993, 46, 881-887.
209. Willner P.: The dopamine hypothesis of schizophrenia: current status, future prospects. Int. Clin. Psychopharmacol., 1997, 12, 297-308.
210. Yamamoto B.K., Cooperman M.A: Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci., 1994, 14, 4159-4166.
211. Yonezawa Y., Kuroki T., Kawahara T., Tashiro N., Uchimura H.: Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur. J. Pharmacol., 1998, 341, 45-56.
212. Yu B., Wang C., Liu J., Johnson K.M., Gallagher J.P.: Adaptation to chronic PCP results in hyperfunctional NMDA and hypofunctional GABA(A) synaptic receptors. Neuroscience, 2002, 113, 1-10.
213. Zhang J., Chiodo L.A., Freeman A.S.: Electrophysiological effect of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res., 1992, 590, 153-163.